Oregon 2023 Regular Session

Oregon Senate Bill SB922

Introduced
2/16/23  
Refer
2/20/23  

Caption

Relating to screening for disease.

Impact

The passage of SB 922 could have significant implications for state health policy, particularly as it emphasizes proactive disease screening and prevention. By mandating an official study, the bill aligns with broader public health goals to enhance care delivery and early detection of health conditions. The findings could inform legislative recommendations that may affect funding, resources, and strategies utilized by health care providers in Oregon. If adopted, such recommendations could lead to changes in existing health regulations and practices across the state.

Summary

Senate Bill 922 requires the Oregon Health Authority to conduct a study focusing on the benefits and risks associated with health care providers screening for various diseases, specifically including osteoporosis. The bill directs the authority to report its findings to the interim committees related to health care by September 15, 2024. This initiative aims to evaluate the effectiveness of screening practices and potentially inform future legislative actions regarding disease management and prevention in Oregon, ultimately fostering better health outcomes for residents.

Sentiment

The sentiment surrounding SB 922 appears to be largely positive, as it promotes an evidence-based approach to health care. Supporters likely recognize the value in exploring effective preventive strategies and may view the bill as a necessary step towards improving public health response to chronic diseases. Nonetheless, there may be concerns regarding the allocation of resources and the potential burden on the Oregon Health Authority to conduct the study within the specified timeframe.

Contention

While there does not seem to be overtly contentious issues highlighted in the bill's text, challenges may arise during implementation, particularly around the adequacy of funding and staffing at the Oregon Health Authority to complete the study effectively. Additionally, debates could emerge about the scope of diseases to be included in the screening initiative. As the bill is scheduled to be repealed on January 2, 2025, there is a limited timeframe for the authorities to conduct their analysis and prepare actionable recommendations, which could lead to discussions about the feasibility and urgency of the tasks assigned.

Companion Bills

No companion bills found.

Previously Filed As

OR HB2927

Relating to sickle cell disease.

OR HB2617

Relating to newborn bloodspot screening; declaring an emergency.

OR SB276

Relating to reimbursements for vision screenings of students; declaring an emergency.

OR HB4109

Relating to newborn bloodspot screening.

OR HB2978

Relating to Parkinson's disease registry; prescribing an effective date.

OR HB2047

Relating to the Rare Disease Advisory Council.

OR SB1099

Newborn screening: genetic diseases: blood samples collected.

OR SB718

Relating to Parkinson's disease registry; prescribing an effective date.

OR HB2595

Relating to Parkinson's disease registry; prescribing an effective date.

OR AB242

Genetic disease screening.

Similar Bills

No similar bills found.